drugset / Trial / NCT02138383

Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer

NCT02138383

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to find out the dose of enzalutamide that can be safely given with gemcitabine and nab-paclitaxel in patients with advanced pancreatic cancer. Researchers also want to find out the side effects of these drugs when given together. This study will help in finding out the effect on tumor of the combination of enzalutamide, gemcitabine and nab-paclitaxel. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.

Timeline

Start
2014-05-22
Primary completion
2016-12-15
Completion
2019-10-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Enzalutamide Other / unclassified 80 mg Oral
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Paclitaxel Small molecule 125 mg/m2 Intravenous